Every 424B that bioAffinity Technologies, Inc. (BIAF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BIAF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIAF filings page.
bioAffinity Technologies (BIAF) is offering 116,545 common shares and up to 536,836 pre-funded warrants; the supplement also registers 536,836 underlying shares. Each pre-funded warrant sold reduces common shares offered one-for-one. The share price is $6.122; each pre-funded warrant costs $6.115 and has a $0.007 exercise price. They are immediately exercisable, subject to a 4.99% beneficial-ownership limit or 9.99% at a holder’s election.
The company intends net proceeds for working capital and general corporate purposes, including laboratory test and therapeutic product development, general and administrative matters, and capital expenditures. It states immediate net tangible book value dilution to common-share purchasers of $1.32 per share. Separately, it is selling up to 980,072 unregistered warrants in a concurrent private placement, exercisable at $6.122 per share beginning on stockholder approval and for five years thereafter. Audited statements for the years ended December 31, 2025 and December 31, 2024 include an explanatory paragraph citing conditions that raise substantial doubt about the company’s ability to continue as a going concern.
bioAffinity Technologies, Inc. (BIAF) reduced to $0 the dollar amount of common stock it may sell under its at-the-market agreement with WallachBeth Capital LLC. From and after October 8, 2026, it may not offer or sell shares under that agreement; it may file a further supplement to increase the amount if its capacity under General Instruction I.B.6 of Form S-3 increases. During the prior twelve-calendar-month period ending on and including the supplement date, the company offered and sold $1,800,000 of common stock under that instruction. While non-affiliate market value is less than $75,000,000, sales under the instruction are limited to one-third of aggregate market value in any 12-month period; reported non-affiliate market value was approximately $17,707,550 as of October 8, 2026.
bioAffinity Technologies is offering 1,040,000 shares of common stock at $0.80 per share and registering up to 2,960,000 pre-funded warrants exercisable at $0.007 to prevent purchasers exceeding 4.99% (or 9.99% by election) ownership. The prospectus states estimated net proceeds of approximately $2.6 million and a Placement Agent fee of 7.5%.
The offering includes Placement Agent Warrants equal to 3.0% of shares sold at an exercise price of $0.88. Shares outstanding were 4,743,061 as of June 16, 2026, and would be 8,743,061 assuming full exercise of pre-funded warrants sold hereunder.
bioAffinity Technologies, Inc. is registering 497,483 shares of Common Stock for resale by selling stockholders pursuant to this prospectus. The shares comprise 365,603 Warrant Shares issuable upon anti-dilution adjustments to outstanding warrants and 131,880 Conversion Shares issuable upon anti-dilution adjustments to Series B Convertible Preferred Stock.
The company is not offering any shares for its own account and will not receive proceeds from resales by the selling stockholders; the company would receive cash only if the related Warrants are exercised for cash. Share counts in this prospectus assume conversion/exercise for resale purposes and state 4,498,675 shares outstanding as of December 31, 2025, rising to 4,996,155 shares after the offering per the offering table.